Agentic AI: Shifting Medical Affairs from What’s Happening to Why
As healthcare data explodes, agentic AI has emerged as a solution to validate medical information…
Agentic AI: Shifting Medical Affairs from What’s Happening to Why
As healthcare data explodes, agentic AI has emerged as a solution to validate medical information through specialized agents working together behind the scenes. The post Agentic AI: Shifting Medical Affairs from What’s Happening to Why appeared first on MedCity News.
Top-Rated Physical Therapy Clinics Specializing in Stroke Recovery
[Sponsored] The top-rated U.S. organizations with the best physical therapy for stroke recovery are known for structured brain injury rehabilitation programs, multidisciplinary teams and measurable outcomes. The post Top-Rated Physical Therapy Clinics Specializing in Stroke Recovery appeared first on MedCity News.
A Playbook for Modern Ambulatory Infusion Care: How Providers Can Strengthen Experience, Outcomes, and Operational Performance
As specialty therapies expand and chronic conditions rise, infusion services must be viewed as both clinically intensive and deeply human. The post A Playbook for Modern Ambulatory Infusion Care: How Providers Can Strengthen Experience, Outcomes, and Operational Performance appeared first on MedCity News.
As Insurance Prices Rise, Families Puzzle Over Options
New York-based performer Cynthia Freeman, 61, has been trying to figure out how to keep the Affordable Care Act health plan that she and her husband depend on. “If we didn’t have health issues, I’d just go back to where I was in my 40s and not have health insurance,” she said, “but we’re not…
How Is Your County Spending Opioid Settlement Cash? Our Tracking Tool Follows the Money.
LISTEN: Big cuts to Medicaid mean some states will have to scramble to keep offering treatment for addiction. KFF Health News senior correspondent Aneri Pattani appeared on WAMU’s “Health Hub” on Jan. 14 to explain why addiction care advocates worry opioid settlement money could end up plugging holes in state budgets instead of fighting the…
Hospitals can soften the blow of Medicaid’s retroactive coverage change, if they choose to
By BRIAN STANLEY Patients waiting on Medicaid enrollment face more bills, while Congress touts that as cost savings. Hospitals need to choose their stance. Medicaid covers the lion’s share of short- and long-term health care expenses for low-income, older, and/or disabled Americans. Until now, the program paid for care received up to three months before…
A Guide to Noninvasive Liver Diagnostic Devices: Technology and Leading Organizations Explained
[Sponsored] The leading device-based solutions showcase this innovative technology and offer numerous clinical benefits. Here’s a guide to how they work and what to consider. The post A Guide to Noninvasive Liver Diagnostic Devices: Technology and Leading Organizations Explained appeared first on MedCity News.
Kaiser Permanente to Pay $556M to Settle Medicare Advantage Fraud Allegations
Five Kaiser Permanente affiliates agreed to pay $556 million to settle allegations from the Department of Justice that they improperly inflated Medicare Advantage payments through inaccurate diagnosis coding. The case is one of the largest risk-adjustment settlements to date — and it signals continued federal scrutiny of the program. The post Kaiser Permanente to Pay…
Takeda R&D Exec Explains How $1.2B Deal Could Become One of the Biggest Bargains in Drug History
Bispecific antibodies are one of the hottest areas for drug research and dealmaking, and several of them were discussed this week during the annual J.P. Morgan Healthcare Conference in San Francisco. Takeda President, Research and Development, Andy Plump talked to MedCity News about what sets the Japanese pharma company’s newly licensed drug apart. The post…
How is AI transforming the pharmaceutical industry?
The Economist reports that many life science companies are betting big on AI to help with drug development. Why? If AI can increase their likelihood new molecules become successful drugs, the cost of drug development will fall. AI-designed molecules show an 80-90% success rate in early-stage safety trials, compared with a historical average of just…
